Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53.
Google Scholar
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.
Google Scholar
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–90.
Google Scholar
Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396–407.
Google Scholar
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–23.
Google Scholar
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.
Google Scholar
Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.
Google Scholar
Kondo E. Autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma. J Clin Exp Hematop. 2016;56:100–8.
Google Scholar
Rassy E, Danu A, Ibrahim T, Lazarovici J, Ghez D, Michot JM, et al. Outcomes of transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: the Gustave Roussy experience. Clin Lymphoma Myeloma Leuk. 2021;21:e373–80.
Google Scholar
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–6.
Google Scholar
Lorenc R, Shouval R, Flynn JR, Devlin SM, Saldia A, De Abia AL, et al. Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma. Transpl Cell Ther. 2024;30:990–1000.
Google Scholar
Strussmann T, Marks R, Wasch R Relapsed/refractory diffuse Large B-cell lymphoma: is there still a role for autologous stem cell transplantation in the CAR T-Cell era? Cancers 2024;16:1987.
Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94:710–25.
Google Scholar
Navarro A, Bea S, Jares P, Campo E. Molecular pathogenesis of mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34:795–807.
Google Scholar
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.
Google Scholar
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659–67.
Google Scholar
Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988–97.
Google Scholar
Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139:3148–58.
Google Scholar
Handunnetti SM, Anderson MA, Burbury K, Thompson PA, Burke G, Bressel M, et al. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 2024;144:867–72.
Google Scholar
Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, et al. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma. Int J Clin Oncol. 2024;29:232–40.
Google Scholar
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331–42.
Google Scholar
Ahmed G, Alsouqi A, Szabo A, Samples L, Shadman M, Awan FT, et al. CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024;8:3528–31.
Google Scholar
Zhu F, Rui L. PRMT5 in gene regulation and hematologic malignancies. Genes Dis. 2019;6:247–57.
Google Scholar
Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20:509–30.
Google Scholar
Zheng J, Li B, Wu Y, Wu X, Wang Y. Targeting arginine methyltransferase PRMT5 for cancer therapy: updated progress and novel strategies. J Med Chem. 2023;66:8407–27.
Google Scholar
Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontan L, et al. PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood. 2018;132:2026–39.
Google Scholar
Che Y, Liu Y, Yao Y, Hill HA, Li Y, Cai Q, et al. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations. Blood Cancer J. 2023;13:27.
Google Scholar
Zhu F, Guo H, Bates PD, Zhang S, Zhang H, Nomie KJ, et al. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Leukemia. 2019;33:2898–911.
Google Scholar
Sloan SL, Brown F, Long M, Weigel C, Koirala S, Chung JH, et al. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma. Blood. 2023;142:887–902.
Google Scholar
Liang JH, Wang WT, Wang R, Gao R, Du KX, Duan ZW, et al. PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma. Cancer Lett. 2024;591:216877.
Google Scholar
Yin S, Liu L, Brobbey C, Palanisamy V, Ball LE, Olsen SK, et al. PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis. Nat Commun. 2021;12:3444.
Google Scholar
Huang L, Zhang XO, Rozen EJ, Sun X, Sallis B, Verdejo-Torres O, et al. PRMT5 activates AKT via methylation to promote tumor metastasis. Nat Commun. 2022;13:3955.
Google Scholar
Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015;11:432–7.
Google Scholar
Vieito M, Moreno V, Spreafico A, Brana I, Wang JS, Preis M, et al. Phase 1 Study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors. Clin Cancer Res. 2023;29:3592–602.
Google Scholar
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.
Google Scholar
Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266–82.
Google Scholar
Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9:55.
Google Scholar
Liang D, Minikes AM, Jiang X. Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell. 2022;82:2215–27.
Google Scholar
Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22:381–96.
Google Scholar
Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42:513–34.
Google Scholar
Schmitt A, Xu W, Bucher P, Grimm M, Konantz M, Horn H, et al. Dimethyl fumarate induces ferroptosis and impairs NF-kappaB/STAT3 signaling in DLBCL. Blood. 2021;138:871–84.
Google Scholar
Schmitt A, Grimm M, Kreienkamp N, Junge H, Labisch J, Schuhknecht L, et al. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood. 2023;142:1143–55.
Google Scholar
Liu Y, Kimpara S, Hoang NM, Daenthanasanmak A, Li Y, Lu L, et al. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma. Blood. 2023;142:1879–94.
Google Scholar
Hoang NM, Liu Y, Bates PD, Heaton AR, Lopez AF, Liu P, et al. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma. Cell Rep Med. 2024;5:101484.
Google Scholar
Fan Y, Wang Y, Dan W, Zhang Y, Nie L, Ma Z, et al. PRMT5-mediated arginine methylation stabilizes GPX4 to suppress ferroptosis in cancer. Nat Cell Biol. 2025;27:641–53.
Google Scholar
McCord R, Bolen CR, Koeppen H, Kadel EE III, Oestergaard MZ, et al. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019;3:531–40.
Google Scholar
Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, et al. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017;35:1668–77.
Google Scholar
Slavin MB, Kumari R, Hood DA. ATF5 is a regulator of exercise-induced mitochondrial quality control in skeletal muscle. Mol Metab. 2022;66:101623.
Google Scholar
Jiang H, Wang C, Zhang A, Li Y, Li J, Li Z, et al. ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis. Biomed Pharmacother. 2022;153:113280.
Google Scholar
He F, Zhang P, Liu J, Wang R, Kaufman RJ, Yaden BC, et al. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J Hepatol. 2023;79:362–77.
Google Scholar
Zhang X, Li Z, Zhang X, Yuan Z, Zhang L, Miao P. ATF family members as therapeutic targets in cancer: From mechanisms to pharmacological interventions. Pharm Res. 2024;208:107355.
Google Scholar
Yamazaki T, Ohmi A, Kurumaya H, Kato K, Abe T, Yamamoto H, et al. Regulation of the human CHOP gene promoter by the stress response transcription factor ATF5 via the AARE1 site in human hepatoma HepG2 cells. Life Sci. 2010;87:294–301.
Google Scholar
Mo H, Guan J, Mo L, He J, Wu Z, Lin X, et al. ATF4 regulated by MYC has an important function in anoikis resistance in human osteosarcoma cells. Mol Med Rep. 2018;17:3658–66.
Google Scholar
Ding J, Bansal M, Cao Y, Ye B, Mao R, Gupta A, et al. MYC drives mRNA pseudouridylation to mitigate proliferation-induced cellular stress during cancer development. Cancer Res. 2024;84:4031–48.
Google Scholar
Kimpara S, Lu L, Hoang NM, Zhu F, Bates PD, Daenthanasanmak A, et al. EGR1 addiction in diffuse large B-cell lymphoma. Mol Cancer Res. 2021;19:1258–69.
Google Scholar
Martinez-Martin S, Beaulieu ME, Soucek L. Targeting MYC-driven lymphoma: lessons learned and future directions. Cancer Drug Resist. 2023;6:205–22.
Google Scholar
Hermida MA, Dinesh Kumar J, Leslie NR. GSK3 and its interactions with the PI3K/AKT/mTOR signalling network. Adv Biol Regul. 2017;65:5–15.
Google Scholar
Shoeb M, Ansari NH, Srivastava SK, Ramana KV. 4-Hydroxynonenal in the pathogenesis and progression of human diseases. Curr Med Chem. 2014;21:230–7.
Google Scholar
Yu T, Xu-Monette ZY, Yu L, Li Y, Young KH. Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma. Cell Death Dis. 2023;14:771.
Google Scholar
Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861–74.
Google Scholar
Rui L, Drennan AC, Ceribelli M, Zhu F, Wright GW, Huang DW, et al. Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2016;113:E7260–E7267.
Google Scholar
Cao M, Lai P, Liu X, Liu F, Qin Y, Tu P, et al. ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma. Front Immunol. 2023;14:1282996.
Google Scholar
Wang LN, Tang YL, Zhang YC, Zhang ZH, Liu XJ, Ke ZY, et al. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways. Leuk Lymphoma. 2017;58:2426–38.
Google Scholar
Ishihara S, Enomoto A, Sakai A, Iida T, Tange S, Kioka N, et al. Stiff extracellular matrix activates the transcription factor ATF5 to promote the proliferation of cancer cells. iScience. 2025;28:112057.
Google Scholar
Zhou J, Tian H, Zhi X, Xiao Z, Chen T, Yuan H, et al. Activating transcription factor 5 (ATF5) promotes tumorigenic capability and activates the Wnt/b-catenin pathway in bladder cancer. Cancer Cell Int. 2021;21:660.
Google Scholar
Greene LA, Zhou Q, Siegelin MD, Angelastro JM Targeting transcription factors ATF5, CEBPB and CEBPD with cell-penetrating peptides to treat brain and other cancers. Cells 2023;12:581.
Angelastro JM. Targeting ATF5 in cancer. Trends Cancer. 2017;3:471–4.
Google Scholar
